Synapse - Jacqueline Bromberg

Results (19)

Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer

Meeting Abstract

Lyons, T.; Gucalp, A.; Arumov, A.; Patil, S.; Edelweiss, M.; Gorsky, M.; Troso-Sandoval, T. A.; Bromberg, J.; Sanford, R. A.; Iyengar, N. M.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Phase II study of paclitaxel and dasatinib in metastatic breast cancer

Journal Article

Morris, P. G.; Rota, S.; Cadoo, K.; Zamora, S.; Patil, S.; D'Andrea, G.; Gilewski, T.; Bromberg, J.; Dang, C.; Dickler, M.; more...
Clinical Breast Cancer (2018)

Fulltext@MSK | Save

Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer

Journal Article

Gucalp, A.; Sparano, J. A.; Caravelli, J.; Santamauro, J.; Patil, S.; Abbruzzi, A.; Pellegrino, C.; Bromberg, J.; Dang, C.; Theodoulou, M.; more...
Clinical Breast Cancer (2011)

Fulltext@MSK | Save

Phase II trial of saracatinib in patients (pts) with ER/PR-negative metastatic breast cancer (MBC)

Meeting Abstract

Traina, T. A.; Sparano, J. A.; Caravelli, J.; Patil, S.; Abbruzzi, A.; Hawke, R.; Bromberg, J.; Nonemaker, J.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

A phase I-II trial of dasatinib (D) in combination with weekly (w) paclitaxel (P) for patients (Pts) with metastatic breast carcinoma (MBC)

Meeting Abstract

Morris, P. G.; Abbruzzi, A.; D'Andrea, G.; Gilewski, T.; Lake, D.; Bromberg, J.; Dang, C.; Dickler, M.; Modi, S.; Seidman, A. D.; more...
Cancer Research (2010)

Fulltext@MSK | Save

Androgen receptor inhibition can stabilize disease in patients with AR(+), ER(-)/PR(-) metastatic breast cancer

Meeting Abstract

Traina, T. A.; Feigin, K.; Patil, S.; Yuan, J.; Dickler, M.; Andrea, G. D.; Bromberg, J.; Hudis, C.
Annals of Oncology (2009)

Fulltext@MSK | Save

A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer

Journal Article

Dickler, M. N.; Rugo, H. S.; Eberle, C.; Brogi, E.; Caravelli, J.; Panageas, K. S.; Boyd, J.; Yeh, B.; Lake, D. E.; Dang, C.; more...
Clinical Cancer Research (2008)

Fulltext@MSK | Save

Increased dose density is feasible: A pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer

Journal Article

Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C.; Panageas, K. S.; Atienza, M.; Norton, L.; more...
Clinical Cancer Research (2007)

Fulltext@MSK | Save

Increased dose-density (DD) is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10-11 day interval with filgrastim support, for women with early breast carcinoma (BC)

Meeting Abstract

Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C. H.; Panageas, K.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save